NanoViricides Highlights NV-387 at Pharma Partnering Summit 2025

NanoViricides, Inc., a leader in antiviral drug development, is presenting at the Pharma Partnering Summit 2025. The event, held at the Hilton Boston Logan Airport, showcases their revolutionary drug NV-387. This broad-spectrum antiviral targets over 90% of pathogenic viruses using heparan sulfate features that mimic natural viral entry receptors.

NV-387 is in Phase II trials and has shown promise against various viruses, including Influenza H3N2 and RSV. Compared to Tamiflu and Xofluza, NV-387 demonstrated superior efficacy in animal studies. Additionally, it could be pivotal if bird flu H5N1 strains mutate to affect humans.

The company's pipeline includes NV-HHV-1 for herpes viruses and NV-HIV-1 for HIV treatment. NanoViricides' platform also supports drug delivery innovations and potential rescues of existing pharmaceutical candidates.